Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes.

Journal: eLife
PMID:

Abstract

Drug-induced cardiotoxicity and hepatotoxicity are major causes of drug attrition. To decrease late-stage drug attrition, pharmaceutical and biotechnology industries need to establish biologically relevant models that use phenotypic screening to detect drug-induced toxicity in vitro. In this study, we sought to rapidly detect patterns of cardiotoxicity using high-content image analysis with deep learning and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). We screened a library of 1280 bioactive compounds and identified those with potential cardiotoxic liabilities in iPSC-CMs using a single-parameter score based on deep learning. Compounds demonstrating cardiotoxicity in iPSC-CMs included DNA intercalators, ion channel blockers, epidermal growth factor receptor, cyclin-dependent kinase, and multi-kinase inhibitors. We also screened a diverse library of molecules with unknown targets and identified chemical frameworks that show cardiotoxic signal in iPSC-CMs. By using this screening approach during target discovery and lead optimization, we can de-risk early-stage drug discovery. We show that the broad applicability of combining deep learning with iPSC technology is an effective way to interrogate cellular phenotypes and identify drugs that may protect against diseased phenotypes and deleterious mutations.

Authors

  • Francis Grafton
    Tenaya Therapeutics, South San Francisco, United States.
  • Jaclyn Ho
    Tenaya Therapeutics, South San Francisco, United States.
  • Sara Ranjbarvaziri
    Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, United States.
  • Farshad Farshidfar
    Tenaya Therapeutics, South San Francisco, United States.
  • Anastasiia Budan
    Tenaya Therapeutics, South San Francisco, United States.
  • Stephanie Steltzer
    Tenaya Therapeutics, South San Francisco, United States.
  • Mahnaz Maddah
    Dana Solutions, Palo Alto, United States.
  • Kevin E Loewke
    Dana Solutions, Palo Alto, United States.
  • Kristina Green
    Tenaya Therapeutics, South San Francisco, United States.
  • Snahel Patel
    Tenaya Therapeutics, South San Francisco, United States.
  • Tim Hoey
    Tenaya Therapeutics, South San Francisco, United States.
  • Mohammad Ali Mandegar
    Tenaya Therapeutics, South San Francisco, United States.